Feb 25 (Reuters) - Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as
Rovi Net Profit Up 3% on Strong Okedi and Heparin Sales in 2025
Okedi and Heparin Sales
Net Profit Up 3%
Earnings and Sales Drivers
Feb 25 (Reuters) - Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as recognition of R&D aid - offset a decline in contract manufacturing revenue.
* Full-year net profit rose to 140.4 million euros, whileoperating revenue fell 3% to 743.5 million euros * CDMO revenue dropped 20% to 269.5 million euros onnegligible Moderna-related revenue and lower production volumesfor Moderna * Specialty pharmaceutical revenue increased 11% to 473.9million euros, driven by a 97% rise in Okedi sales and 7% in theheparin franchise, which includes low molecular weight heparins(LMWH) and other heparins * Gross profit rose 3% to 494.7 million euros, supported by36.3 million euros in R&D aid and lower LMWH raw material prices * Rovi will propose a dividend of 0.96 euros per share, apayout of around 35% * It expects 2026 operating revenue to grow by a highsingle-digit to low double-digit percentageReporting and Editing Credits
(Reporting by Marta Serafinko in Gdansk; Editing by David Latona)
